HRP20200136T1 - Farmaceutski pripravci i metode za njihovu stabilizaciju - Google Patents
Farmaceutski pripravci i metode za njihovu stabilizaciju Download PDFInfo
- Publication number
- HRP20200136T1 HRP20200136T1 HRP20200136TT HRP20200136T HRP20200136T1 HR P20200136 T1 HRP20200136 T1 HR P20200136T1 HR P20200136T T HRP20200136T T HR P20200136TT HR P20200136 T HRP20200136 T HR P20200136T HR P20200136 T1 HRP20200136 T1 HR P20200136T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- clevidipine
- soybean oil
- emulsion
- amount
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 12
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 claims 6
- 229960003597 clevidipine Drugs 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- 235000012424 soybean oil Nutrition 0.000 claims 5
- 239000003549 soybean oil Substances 0.000 claims 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 239000000839 emulsion Substances 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 3
- 230000003647 oxidation Effects 0.000 claims 3
- 238000007254 oxidation reaction Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000003860 storage Methods 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 239000008346 aqueous phase Substances 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 239000011261 inert gas Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- 235000019198 oils Nutrition 0.000 claims 2
- 239000012071 phase Substances 0.000 claims 2
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 235000013345 egg yolk Nutrition 0.000 claims 1
- 210000002969 egg yolk Anatomy 0.000 claims 1
- 229940068998 egg yolk phospholipid Drugs 0.000 claims 1
- 239000008344 egg yolk phospholipid Substances 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
1. Postupak priprave farmaceutskog pripravka koji je stabiliziran protiv oksidacije, naznačeno time da pripravak jest emulzija za intravenozno davanje koja sadrži:
0.5 mg po mL klevidipina ili njegove farmaceutski prihvatljive soli,
20% ulja soje,
glicerin,
pročišćeni fosfolipidi iz žumanjka,
voda,
te natrijev hidroksid,
pri čemu postupak obuhvaća korake:
(a) doziranje vode za injekciju u posudu za miješanje pri od 74 °C do 78°C;
(b) dodavanje glicerina u vodu i hlađenje nastale vodene faze na 60 °C do 70 °C;
(c) doziranje ulja soje u posudu za otapanje da bi se dobila uljna faza;
(d) miješanje i zagrijavanje ulja soje na 70 °C do 82 °C;
(e) dodavanje klevidipina u smjesu ulja soje i zagrijavanje na 78 °C do 82 °C;
(f) dodavanje fosfolipida iz žumanjka u smjesu klevidipina i ulja soje;
(g) miješanje vodene faze i uljne faze da nastane emulzija;
(h) podešavanje pH s 1N natrijevim hidroksidom do pH od 6.0 do 8.8; te
(i) homogenzijacija emulzije pri tlaku od 500/8000 psi pri temperaturi od 50 °C do 55 °C; te
pri čemu je oksidacija pripravka minimizirana reduciranjem količine izlaganja svjetlu tijekom procesa proizvodnje i skladištenja, tako da količina H324/78 koja ima sljedeću formulu:
[image]
jest manja od ili jednaka oko 0.2% mase po masi temeljene na klevidipinu.
2. Postupak prema patentnom zahtjevu 1, naznačeno time da je količina H324/78 tolika da je omjer klevidipina, ili njegovih farmaceutski prihvatljivih soli, i H324/78 veći od ili jednak od oko 500 do 1 izraženo kao masa po masi.
3. Postupak prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačeno time da je pripravak stabiliziran skladištenjem u zatamnjenom spremniku, radi reduciranja izlaganja pripravka svjetlu.
4. Postupak prema patentnom zahtjevu 3, naznačeno time da je zatamnjeni spremnik barem djelomično prekriven sekundarnim omotačem.
5. Postupak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time da je oksidacijom uzrokovana degradacija klevidipina ili njegove farmaceutski prihvatljive soli reducirana na brzinu manju od oko 0.5% po danu izraženo kao masa po masi.
6. Postupak prema patentnom zahtjevu 1,
naznačeno time da su komponente prekrivene inertnim plinom tijekom postupka proizvodnje i skladištenja emulzije,
te
pri čemu je pripravak skladišten u zabrtvljenom i zatamnjenom, pigmentiranom, obojenom, neprozirnom ili drugačije zatamnjenom spremniku koji reducira količinu izlaganja svjetlu.
7. Postupak prema patentnom zahtjevu 6, naznačeno time da inertni plin jest dušik.
8. Postupak prema patentnom zahtjevu 6, naznačeno time da je spremnik barem djelomično prekriven sekundarnim omotačem.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8559408P | 2008-08-01 | 2008-08-01 | |
US9381008P | 2008-09-03 | 2008-09-03 | |
PCT/US2009/004399 WO2010014234A1 (en) | 2008-08-01 | 2009-07-30 | Pharmaceutical compositions and methods for stabilizing the same |
EP09803270.9A EP2320739B1 (en) | 2008-08-01 | 2009-07-30 | Pharmaceutical compositions and methods for stabilizing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200136T1 true HRP20200136T1 (hr) | 2020-08-21 |
Family
ID=41610652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200136TT HRP20200136T1 (hr) | 2008-08-01 | 2020-01-29 | Farmaceutski pripravci i metode za njihovu stabilizaciju |
Country Status (21)
Country | Link |
---|---|
US (4) | US20100105743A1 (hr) |
EP (1) | EP2320739B1 (hr) |
JP (4) | JP2011529879A (hr) |
KR (4) | KR20160095206A (hr) |
CN (2) | CN102186351A (hr) |
AU (1) | AU2009277100B2 (hr) |
BR (1) | BRPI0917562B8 (hr) |
CA (1) | CA2732692C (hr) |
CY (1) | CY1122526T1 (hr) |
DK (1) | DK2320739T3 (hr) |
EA (1) | EA201170287A1 (hr) |
ES (1) | ES2770178T3 (hr) |
HR (1) | HRP20200136T1 (hr) |
HU (1) | HUE047692T2 (hr) |
LT (1) | LT2320739T (hr) |
MX (1) | MX2011001241A (hr) |
NZ (1) | NZ591204A (hr) |
PL (1) | PL2320739T3 (hr) |
PT (1) | PT2320739T (hr) |
SI (1) | SI2320739T1 (hr) |
WO (1) | WO2010014234A1 (hr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120100945A (ko) * | 2009-09-30 | 2012-09-12 | 마이크로도스 테라퓨특스, 인코포레이티드 | 레이노 증후군의 치료를 위한 방법들 및 조성물들 |
HUE026295T2 (en) | 2010-10-12 | 2016-06-28 | The Medicines Co | Clevidipine emulsion formulations containing antimicrobial agents |
US8658676B2 (en) | 2010-10-12 | 2014-02-25 | The Medicines Company | Clevidipine emulsion formulations containing antimicrobial agents |
BR112013025368A8 (pt) * | 2011-04-01 | 2018-06-12 | The Medicines Co | Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame |
CN103134891A (zh) * | 2011-11-30 | 2013-06-05 | 天津金耀集团有限公司 | 一种丁酸氯维地平含量和有关物质的测定方法 |
EA030354B1 (ru) | 2012-10-26 | 2018-07-31 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ уменьшения диспноэ у пациента с острой сердечной недостаточностью |
CN103520104B (zh) * | 2013-10-25 | 2015-08-26 | 北京蓝丹医药科技有限公司 | 丁酸氯维地平脂肪乳注射液及其制备方法 |
CN109776405A (zh) * | 2019-03-07 | 2019-05-21 | 重庆安格龙翔医药科技有限公司 | 一种丁酸氯维地平杂质的制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE756779A (fr) * | 1969-09-30 | 1971-03-01 | Warner Lambert Pharmaceutical | Solutions stables de cardenolides sensibles a l'oxydation |
US4150744A (en) * | 1976-02-27 | 1979-04-24 | Smith & Nephew Pharmaceuticals Ltd. | Packaging |
DE3532129A1 (de) * | 1985-09-10 | 1987-03-12 | Bayer Ag | Ss-carotin enthaltende gelatine |
US5651991A (en) * | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
AU614465B2 (en) * | 1989-04-05 | 1991-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
SE9303744D0 (sv) * | 1993-11-12 | 1993-11-12 | Astra Ab | Pharmaceutical emulsion |
SE9804002D0 (sv) | 1998-11-23 | 1998-11-23 | Astra Ab | New manufacturing process |
JP2000247883A (ja) * | 1999-02-23 | 2000-09-12 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジン系化合物を含有する内服用液剤 |
US20030102246A1 (en) * | 1999-03-20 | 2003-06-05 | Lts Lohmann Therapie-Systeme Ag | Method for improving the stability of stored and/or used light-sensitive therapeutic systems or components thereof |
US6956048B2 (en) * | 1999-03-31 | 2005-10-18 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
US6680334B2 (en) * | 2001-08-28 | 2004-01-20 | Pfizer Inc | Crystalline material |
JP2003104888A (ja) * | 2001-09-28 | 2003-04-09 | Taiyo Yakuhin Kogyo Kk | ジヒドロピリジン誘導体の錠剤 |
DE10224612A1 (de) * | 2002-06-04 | 2003-12-24 | Lohmann Therapie Syst Lts | Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung |
ES2294330T3 (es) * | 2002-08-02 | 2008-04-01 | MERCK & CO., INC. | Derivados de furo(2,3-b)piridina sustituidos. |
EP1635773A2 (en) * | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. (a New Jersey corp.) | Combination therapy for the treatment of hypertension |
TW200613275A (en) * | 2004-08-24 | 2006-05-01 | Recordati Ireland Ltd | Lercanidipine salts |
JP4509118B2 (ja) * | 2004-10-06 | 2010-07-21 | エルメッド エーザイ株式会社 | 医薬組成物及びその製造方法、並びに医薬組成物におけるジヒドロピリジン系化合物の安定化方法 |
US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
BRPI0614417A2 (pt) * | 2005-07-28 | 2011-03-29 | Reliant Pharmaceuticals Inc | composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas |
CN101484006A (zh) * | 2006-04-18 | 2009-07-15 | Ekr治疗公司 | 预混和的、立即可用的ⅳ推注组合物和使用方法 |
-
2009
- 2009-07-30 KR KR1020167021112A patent/KR20160095206A/ko active Application Filing
- 2009-07-30 PL PL09803270T patent/PL2320739T3/pl unknown
- 2009-07-30 AU AU2009277100A patent/AU2009277100B2/en active Active
- 2009-07-30 KR KR1020187014941A patent/KR101946977B1/ko active IP Right Grant
- 2009-07-30 DK DK09803270.9T patent/DK2320739T3/da active
- 2009-07-30 MX MX2011001241A patent/MX2011001241A/es unknown
- 2009-07-30 EP EP09803270.9A patent/EP2320739B1/en active Active
- 2009-07-30 BR BRPI0917562A patent/BRPI0917562B8/pt active IP Right Grant
- 2009-07-30 EA EA201170287A patent/EA201170287A1/ru unknown
- 2009-07-30 WO PCT/US2009/004399 patent/WO2010014234A1/en active Application Filing
- 2009-07-30 CN CN2009801389616A patent/CN102186351A/zh active Pending
- 2009-07-30 JP JP2011521123A patent/JP2011529879A/ja active Pending
- 2009-07-30 NZ NZ591204A patent/NZ591204A/xx unknown
- 2009-07-30 ES ES09803270T patent/ES2770178T3/es active Active
- 2009-07-30 PT PT98032709T patent/PT2320739T/pt unknown
- 2009-07-30 KR KR1020117004355A patent/KR20110059843A/ko active Application Filing
- 2009-07-30 LT LTEP09803270.9T patent/LT2320739T/lt unknown
- 2009-07-30 HU HUE09803270A patent/HUE047692T2/hu unknown
- 2009-07-30 CN CN201610773076.7A patent/CN106377501A/zh active Pending
- 2009-07-30 CA CA2732692A patent/CA2732692C/en active Active
- 2009-07-30 SI SI200932033T patent/SI2320739T1/sl unknown
- 2009-07-30 KR KR1020177012094A patent/KR20170051542A/ko active Application Filing
- 2009-07-30 US US12/462,147 patent/US20100105743A1/en not_active Abandoned
-
2012
- 2012-08-30 US US13/600,083 patent/US20120322836A1/en not_active Abandoned
-
2015
- 2015-01-23 JP JP2015010907A patent/JP2015098472A/ja not_active Withdrawn
-
2016
- 2016-08-29 JP JP2016166426A patent/JP2016216501A/ja active Pending
-
2017
- 2017-01-11 JP JP2017002785A patent/JP6537538B2/ja active Active
-
2018
- 2018-12-21 US US16/229,654 patent/US20190117660A1/en not_active Abandoned
-
2019
- 2019-12-20 CY CY20191101341T patent/CY1122526T1/el unknown
-
2020
- 2020-01-29 HR HRP20200136TT patent/HRP20200136T1/hr unknown
-
2023
- 2023-05-30 US US18/203,381 patent/US20230302002A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200136T1 (hr) | Farmaceutski pripravci i metode za njihovu stabilizaciju | |
ES2294197T3 (es) | Formulacion de capsula oral con estabilidad fisica aumentada. | |
ES2748934T3 (es) | Cápsula sin costura | |
US20100099639A1 (en) | W/o/w emulsion composition | |
EP2663295B1 (en) | Highly concentrated liquid acetaminophen solutions | |
HRP20090341T1 (hr) | Mekane kapsule koje sadrže palonosetron hidroksiklorid s poboljšanom stabilnosti i bioraspoloživosti | |
ES2638836T3 (es) | Preparación de ED-71 | |
CN103393631A (zh) | 一种氟比洛芬酯药物组合物 | |
KR20170040340A (ko) | 장용성 심리스 소프트 캡슐의 제조 방법 | |
HRP20210138T1 (hr) | Oftalmološki pripravci koji sadrže prostamid koji oslobađa dušikov oksid | |
ES2224869B1 (es) | Composiciones farmaceuticas con actividad antibiotica. | |
ES2828509A1 (es) | Composicion para la impresion 3d de farmacos semisolidos | |
MXPA02009336A (es) | Solucion parenteral que contiene amiodarona. | |
CA2885979A1 (en) | Pharmaceutical formulations of pilocarpine | |
CN101132762A (zh) | 生产含有nsaid的糖锭的方法,其组合物,其治疗用途 | |
US20200138767A1 (en) | Hydroxycitric acid compounds and capsule liquid delivery | |
CN107106568A (zh) | 稠合氨基二氢噻嗪衍生物的药物组合物 | |
JP2003505424A5 (hr) | ||
WO2015003109A1 (en) | Capsule formulation comprising fexofenadine | |
KR101564928B1 (ko) | 나프록센을 유효 성분으로 함유하는 안정성 및 용출률이 개선된 연질캡슐 조성물 | |
JP5360610B2 (ja) | ミノキシジル含有製剤 | |
JP2004196671A (ja) | 水溶性アズレン含有点眼剤 | |
CN102204908A (zh) | 一种含依达拉奉化合物的药物组合物及其制备方法 | |
IT201700009711A1 (it) | Sodium free Diclofenac potassium oral solutions Soluzioni orali di Diclofenac potassico prive di sodio | |
US20230285369A1 (en) | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |